Viridian Therapeutics Inc (VRDN)
29.19
-0.72%
Viridian Therapeutics Inc (VRDN) is currently trading at $29.19. This represents a loss of 0.72% from the previous session. With a market capitalization of $2.78B, VRDN is a key component of the Health Care sector. Investors looking to trade VRDN should compare margin rates and options platforms to optimize their portfolio management.
Broker Promotion
Claim Your $300 Cash Bonus →
T&Cs Apply. Trade VRDN commission-free.
Trading Platform Comparison
Moomoo
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Good for small traders
IBKR
- Min Deposit: $0
- Commissions: $0–$0.005/share
- Fractional Shares: ✅
- Options: ✅
- Notes: Professional-level tools
Ameritrade
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Strong research tools
Webull
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Easy mobile app
AI Market Sentiment
As of today, Viridian Therapeutics Inc (VRDN) shows a bearish trend. Analysts are watching the 30.33 level closely.
Fundamentals
Mkt Cap2.78B
P/E Ratio0.0000
Volume411,529
60-Day Technical Chart
Advanced Charting
Need more indicators for VRDN? Use the world's #1 platform.
Open VRDN on TradingView →Charting Platforms
TradingView
Advanced charts & indicators, web & mobile
StockCharts
Technical analysis charts with overlays & indicators
BarCharts
Market data, charts, and technical signals
Finviz
Visual stock charts & heatmaps
Yahoo Finance Charts
Basic interactive charts with indicators
Side-by-Side: Stocks Near $29
| Metric |
VRDN -0.72% |
FIG +9.30% |
T -1.32% |
PFE -0.63% |
|---|---|---|---|---|
| Price | $29.19 | $30.00 | $27.98 | $26.97 |
| Mkt Cap | $2.78B | $15.62B | $196.89B | $153.46B |
| - | View → | View → | View → |
Latest Headlines
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates
Yahoo Finance • Nov 5, 2025
Goldman Sachs reiterates Buy rating on Viridian Therapeutic stock
Investing.com • Dec 18, 2025
Viridian Therapeutics, Inc. (VRDN) Stock Surges on Dec. 15, 2025: Latest News, Analyst Forecasts, and 2026 Catalysts
TechStock² • Dec 15, 2025
Biotech grants stock options to new hire amid rare disease drug push
Stock Titan • Jan 8, 2026
Viridian Therapeutics (VRDN) Receives Updated Analyst Rating fro
GuruFocus • Feb 3, 2026
● Gemini Agentic AI Analyst Insight for VRDN
Market Education
- I am a newbie Trader, how do I start trading Jul 15, 2023
- The Eagle’s Eye: Spotting Market Opportunities from Above Sep 8, 2025
- The Animal Trading Playbook Sep 8, 2025
External Research